fda warning letters glp-1 compounders september 2025 issued 30 to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's crackdown on misleading FDA Warns Telehealth Firms Over

Genetic insights should always be interpreted with a qualified healthcare provider and never used in isolation

The FDA published an updated Import Alert 66-80 on June 22, 2026, expanding the list of bulk-drug-substance manufacturers subject to Detention Without Physical Examination at the U.S

Unapproved, compounded versions dont have any of that oversight

Florida, 2011: A dozen individuals in South Florida developed streptococcus endophthalmitis infections after eye injections of bevacizumab prepared by a compounding pharmacy

Overall experience: From sign-up to refill, how seamless and human is the care

Abstract Purpose of Review This review summarizes recent advances in the clinical applications of glucagon-like peptide-1 receptor agonists (GLP-1RAs) beyond their established role in glycemic control for type 2 diabetes (T2DM)